Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 0 % of short-term debt in 2025; threshold 65 %.
-
Not on Peppol Peppol
Not registered in the Peppol network, mandatory for VAT-liable companies since 1 January 2026.
Financials
Financial year 2025
JUVISE PHARMACEUTICAL from Brussel, company number BE0863588327, closed financial year 2025 with a result of € -1,303 after tax. For that financial year JUVISE PHARMACEUTICAL recorded a gross margin of € -1,252 and equity of € -227,678. Compared with financial year 2024, the result moved from € -2,288 to € -1,303. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on September 29, 2026.
€ -227,678
▼ € 1,303 vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -1,303
▲ 43 % less loss than in 2024
Profit after tax over the fiscal year.
€ 564
▼ 23% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -233,878.
People and assets in 2025
≈ 1
No payroll staff. One director, so that person most likely runs the business.
Debts at end 2025
None
No bank loans on the last day of the fiscal year.
€ 1,252
▲ € 1,133 vs 2024
Supplier invoices still open on the last day of the fiscal year.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € -1,366 | € -1,478 | € -2,246 | € -1,252 | ▲ € 994 |
| Profit after taxes | € -1,420 | € -1,521 | € -2,288 | € -1,303 | ▲ € 985 |
| Equity | € -222,566 | € -224,087 | € -226,375 | € -227,678 | ▼ € 1,303 |
| Total debts | € 222,989 | € 224,489 | € 227,108 | € 228,241 | |
| Cash | € 423 | € 402 | € 734 | € 564 | ▼ 23% |
| Retained profit | € -228,766 | € -230,287 | € -232,575 | € -233,878 | ▼ € 1,303 |
| Balance sheet total | € 423 | € 402 | € 734 | € 564 | ▼ 23% |
Key figures of JUVISE PHARMACEUTICAL, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to JUVISE PHARMACEUTICAL?
What happened at JUVISE PHARMACEUTICAL in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 1,303. filed late Source: NBB ↗
- Frederic Mascha became a director. NBB
- Start of the company according to the CBE. KBO
In short
From € 1,420 loss in 2022 to € 1,303 loss in 2025.
Management
Behind JUVISE PHARMACEUTICAL is Frederic Mascha.
Directors
According to the 2025 annual accounts
Frederic Mascha
Director
since 2013
Establishments
Establishment units
Physical locations of this company
Buro and Design Center, Heizel E 1 box 86
1020 Brussel
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0863.588.327
- VAT number
- BE 0863.588.327
- Registered office
- Buro and Design Center, Heizel E 1 bus 86, 1020 Brussel
- Names & denominations
- JUVISE PHARMACEUTICAL
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 19 June 2003
- Peppol
- Not registered